Recombinant Proteins Market by Application, End-user, and Geography - Forecast and Analysis 2023-2027

Recombinant Proteins Market Forecast 2023-2027

The recombinant proteins market size is estimated to increase by USD 650.96 million and grow at a CAGR of 9.46% between 2022 and 2027. Market growth hinges on several factors, notably the upsurge in chronic diseases, a growing preference for biologics and biosimilars, and advancements in the technology employed for recombinant protein production. However, challenges persist, encompassing complexities in manufacturing and storage, coupled with high costs, alongside the increasing popularity of alternative treatments and the intricate regulatory landscape. With these conditions becoming increasingly prevalent worldwide, there's a heightened demand for advanced therapeutics and treatments, many of which rely on recombinant proteins for effective management. Investments in research and development play a crucial role in driving innovation, leading to the introduction of novel recombinant protein-based therapies to address evolving medical needs.

What will be the Size of the Recombinant Proteins Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

This market report extensively covers market segmentation by application (biotechnology research, drug discovery and development, biopharmaceutical production, and others), end-user (pharma and biotechnology companies, academic and research institutes, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

By Application

The market share growth by the biotechnology research segment will be significant during the forecast period. The broad field of biotechnology involves the use of biological processes, animals, cells, or cell components to develop new technologies. They have contributed to significant advances in biomedical biotechnology. More and more recombinant proteins are being used in laboratories. This includes proteins generated in course-specific research projects as well as commercially available proteins (such as most enzymes used in molecular biology laboratories). Recombinant lysosomal proteins are often made by mammalian cells.  FDA-approved glycosylated lysosomal protein drugs and other drug candidates were developed using plant cell culture. Recombinant lysosomal proteins can be produced using microorganisms such as Saccharomyces cerevisiae and Escherichia coli. There are both scientific and medical uses for recombinant lysosomal proteins, including enzyme replacement therapy. Such factors drive the growth of the market during the forecast period.

Get a glance at the market contribution of various segments View the PDF Sample

The biotechnology research segment was valued at USD 416.71 million in 2017 and continued to grow until 2021. They are a useful resource for understanding how proteins interact with each other. They have demonstrated their efficacy in various laboratory tests such as ELISA, Western blot, and immunohistochemistry (IHC). Enzymatic assays can be created using recombinant proteins. They are also used in food production, agriculture, and biotechnology. In addition, researchers have used genetic techniques to modify proteins to create recombinant therapeutic proteins. In general, the development of biotechnology has facilitated the production for various applications. Such factors drive the growth of the market during the forecast period. 

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The market in the North American region is growing rapidly due to the higher uptake. The major driving force for the market in this region is the increasing prevalence of cancer, autoimmune diseases, metabolic diseases, musculoskeletal diseases, central nervous system diseases, hematological diseases, etc. The prevalence of cardiovascular disease and cancer is increasing worldwide. Therefore, the demographic and economic growth in this region is expected to present great opportunities for the market. Factors such as rising R&D spending, increasing research activity, favorable government funding, and the presence of key players in the region are boosting the market expansion during the forecast period.

Market Dynamics and Customer Landscape

The market is experiencing significant growth driven by several key factors. Firstly, the aging population worldwide has led to an increased prevalence of chronic and genetic diseases, driving the demand for advanced therapeutics and biologics. Additionally, there is a growing inclination towards biologics and biosimilars due to their effectiveness and specificity in targeting diseases. The continuous launch of advanced recombinant products, including biopharmaceuticals and vaccines such as the Covovax vaccine, further propels market growth. Investments in research and development are fostering innovation, enabling the development of novel cancer therapies and treatments for autoimmune diseases. These trends collectively contribute to the expansion of the market, catering to the rising demand for personalized and effective medical solutions. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The growth of the market is primarily propelled by an increase in chronic diseases such as cancer, cardiovascular ailments, and viral infections. As these diseases become more prevalent globally, the demand for advanced therapeutics and treatments rises, with many relying on recombinant proteins for effective management. Investments in research and development are pivotal drivers, fostering innovation and leading to the introduction of novel recombinant protein-based therapies. These investments drive the launch of advanced recombinant products, expanding the therapeutic landscape and enhancing patient care.

Furthermore, the aging population contributes significantly to the market's expansion. With a growing number of elderly individuals worldwide, there is a heightened demand for biologics and biosimilars, as older age groups are more prone to chronic ailments. This demographic shift not only increases the prevalence of chronic diseases but also underscores the importance of biologics and biosimilars in addressing age-related health challenges. Consequently, the inclination towards biologics and biosimilars escalates, further driving growth in the recombinant proteins market.

Significant Market Trends

Growing opportunities from emerging economies is a key trend influencing market growth. With diverse healthcare markets, the rising prevalence of infectious and chronic diseases, and increasing R&D efforts to develop cutting-edge proteomics and genomics methods, emerging markets such as Asia offer great potential for market participants. In addition to these factors, market participants are encouraged to invest in the region of an aging population, rising income levels, improved healthcare infrastructure, rising healthcare costs, and the region's leadership in low-cost manufacturing. Asia's regulatory framework is also more flexible and business-friendly, attracting larger companies that are already struggling with stiff competition in established markets.

Additionally, governments in several emerging countries in Asia are taking steps to raise awareness of cancer and its diagnosis so that it can be detected early. For example, the health minister of the Indian state of Tamil Nadu said that the government of Tamil Nadu will help identify 66% of stage 1 and stage 2 cancer patients by 2030. He said he was working on developing policies for proper treatment. Consequently, such policies are expected to boost the growth of the market during the forecast period. 

Major Market Challenge

A complicated regulatory framework is challenging market growth. Obtaining regulatory approval is often difficult, unpredictable, and subjective. Recombinant proteins are subject to extensive and stringent regulations before approval and commercialization. From a global perspective, the United States currently lags behind other regulated markets, particularly the European Union (EU), in the biosimilar race. The US biosimilar industry continues to attract attention despite the lack of new entrants. The first and most important factor expected to determine the future of biosimilars in the United States has to do with the approval of the regulatory framework within which biosimilar developers must operate. 

In Europe, strict regulations are applied to ensure their safety and effectiveness in protecting people. However,  most European countries have good market traction as the approval process is a bit faster than in the US.  The inability of a provider to provide clinical data showing positive results in a particular region can incur costs, create uncertainty, and confound other studies. This may create barriers for vendors to develop new protein therapeutics in the market and may adversely affect the growth of the market during the forecast period.  

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Recombinant Proteins Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Abcam plc: The company is involved in the production, distribution, and sales of antibodies and protein research tools. It also offers different types of recombinant proteins, such as bioactive grade proteins and others.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

• Airway Therapeutics Inc.
• Amgen Inc.
• Aviva Systems Biology Corp.
• Bio Techne Corp.
• Bio Rad Laboratories Inc.
• BPS Bioscience Inc.
• Elabscience Biotechnology Inc.
• Enzo Biochem Inc.
• GenScript Biotech Corp.
• Grifols SA
• Merck KGaA
• Novartis AG
• Novo Nordisk AS
• OriGene Technologies Inc.
• Prospec Tany Technogene Ltd.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Application Outlook 
  • Biotechnology research
  • Drug discovery and development
  • Biopharmaceutical production
  • Others

• End-user Outlook
  • Pharma and biotechnology companies
  • Academic and research institutes
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • APAC
    • China
    • India
  • Rest of World (ROW)

Market Analyst Overview

The market is witnessing significant growth driven by therapeutic and vaccination measures, particularly in response to infectious diseases. Research and development activities are accelerating, enhancing the efficacy of recombinant protein-based medicine. Investments in this sector are rising, fueled by the prevalence of chronic diseases and the growing inclination towards biologics and biosimilars. The market is witnessing the launch of advanced recombinant products and the development of cancer therapies. However, challenges persist, including time-consuming and high-cost production processes. Despite this, advancements such as protein-on-demand and semi-custom recombinant protein portfolios are shaping the landscape, promising growth in advanced therapeutics.

Furthermore, the market is propelled by public organizations and private investments in research and development, aiming to address various health challenges like leukemia, diabetes, and rare genetic diseases. Advanced technologies like immunoassay kits and recombinant antibody production are enhancing diagnosis and treatment in clinical settings. Additionally, breakthroughs in personalized medicines and regenerative medicine offer promising solutions for conditions such as hemophilia and sclerosis. Despite time-consuming production processes, the market sees FDA approval for innovative products like Ayvakit and the Covovax vaccine, reflecting a growing awareness of health issues and the need for effective biopharmaceuticals in combating diseases like HIV/AIDS and metabolic disorders.

Additionally, the Recombinant Protein Market is witnessing significant growth fueled by advancements in biotechnology. Phage vectors and host cell lines are revolutionizing protein production, while recombinant antibodies and expression systems enhance therapeutic options. Organizations like the International Diabetes Federation (IDF) and Global Genes drive awareness about genetic disorders and diseases like granulomatous disease. Emergency Use Listing (EUL) by regulatory bodies like the Drugs Controller General of India (DCGI) ensures timely access to innovative treatments. Cohort programs and biobanks aid biomarker discovery, advancing healthcare and life sciences, particularly in areas like immunology, neuroscience, and cytokines, addressing diseases such as diabetes and mortality.

Recombinant Proteins Market Scope
Report Coverage	Details
Page number	167
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 9.46%
Market growth 2023-2027	USD 650.96 million
Market structure	Fragmented
YoY growth 2022-2023(%)	9.0
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, Germany, Italy, China, and Japan
Competitive landscape	Leading vendors, market positioning of vendors, competitive strategies, and industry risks
Key companies profiled	Abcam plc, Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Bio Techne Corp., Bio Rad Laboratories Inc., BPS Bioscience Inc., Elabscience Biotechnology Inc., Enzo Biochem Inc., GenScript Biotech Corp., Grifols SA, Merck KGaA, Novartis AG, Novo Nordisk AS, OriGene Technologies Inc., Prospec Tany Technogene Ltd., Proteintech Group Inc., Sanofi SA, Sino Biological Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about vendors
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch